CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023.
Second Quarter 2023 Financial Results Summary:
“Second quarter total net revenue came in above the high-end of the guidance range we provided on our first quarter earnings call,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board of Organogenesis. “As expected, we leveraged our diversified portfolio and leadership position in Wound Care Centers and physician offices across the U.S. to deliver better-than-expected revenue and profitability performance in Q2.”
Mr. Gillheeney continued: “The recently published local coverage determinations (LCDs) from Novitas, First Coast Services and CGS to limit coverage for treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to include only Apligraf and Dermagraft, presents a significant amount of uncertainty regarding the revenue outlook for a number of our products in these regions. Further uncertainty remains as it relates to potential impact on demand for our products when used for treatment of non-DFU/VLU wounds. As such, we are withdrawing the fiscal year 2023 guidance, previously provided on May 10, 2023. We believe that the five commercialized products that were listed as ‘not covered’ were improperly excluded from the list of ‘covered’ products and we are engaging with all relevant parties in advance of the effective date of these LCDs on September 17, 2023.”
Second Quarter 2023 Financial Results:
| Three Months Ended June 30, | Change | |||||||||||||||
| 2023 | 2022 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced Wound Care | $ | 110,075 | $ | 113,791 | $ | (3,716 | ) | (3 | %) | |||||||
| Surgical & Sports Medicine | 7,241 | 7,610 | (369 | ) | (5 | %) | ||||||||||
| Net revenue | $ | 117,316 | $ | 121,401 | $ | (4,085 | ) | (3 | %) | |||||||
Net revenue for the second quarter of 2023 was $117.3 million, compared to $121.4 million for the second quarter of 2022, a decrease of $4.1 million, or 3%. The decrease in net revenue was driven by a decrease of $3.7 million, or 3% in net revenue for Advanced Wound Care products and a decrease of $0.4 million, or 5%, in net revenue for Surgical & Sports Medicine products.
Gross profit for the second quarter of 2023 was $91.0 million, or 78% of net revenue, compared to $94.7 million, or 78% of net revenue for the second quarter of 2022, a decrease of $3.7 million.
Operating expenses for the second quarter of 2023 were $81.3 million compared to $82.8 million for the second quarter of 2022, a decrease of $1.6 million. R&D expense was $10.9 million for the second quarter of 2023, compared to $10.2 million for the second quarter of 2022, an increase of $0.7 million. Selling, general and administrative expenses were $70.3 million for the second quarter of 2023, compared to $72.6 million for the second quarter of 2022, a decrease of $2.3 million.
Operating income for the second quarter of 2023 was $9.7 million, compared to operating income of $11.9 million for the second quarter of 2022, a decrease of $2.2 million.
Total other expense, net, for the second quarter of 2023 was $0.6 million, compared to $0.8 million for the second quarter of 2022, a decrease of $0.2 million.
Net income for the second quarter of 2023 was $5.3 million, or $0.04 per share, compared to net income of $8.7 million, or $0.07 per share, for the second quarter of 2022, a decrease of $3.4 million, or $0.03 per share.
Adjusted net income of $6.1 million for the second quarter of 2023, compared to adjusted net income of $11.3 million for the second quarter of 2022, a decrease of $5.2 million.
Adjusted EBITDA was $15.4 million for the second quarter of 2023, compared to $18.6 million for the second quarter of 2022, a decrease of $3.2 million.
As of June 30th, 2023, the Company had $89.5 million in cash, cash equivalents and restricted cash and $69.0 million in debt obligations, compared to $103.3 million in cash, cash equivalents and restricted cash and $70.8 million in debt obligations as of December 31, 2022.
First Half 2023 Results
The following table represents net revenue by product grouping for the six months ended June 30, 2023 and June 30, 2022, respectively:
| Six Months Ended June 30, | Change | |||||||||||||||
| 2023 | 2022 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced Wound Care | $ | 210,992 | $ | 203,881 | $ | 7,111 | 3 | % | ||||||||
| Surgical & Sports Medicine | 13,966 | 14,637 | (671 | ) | (5 | %) | ||||||||||
| Net revenue | $ | 224,958 | $ | 218,518 | $ | 6,440 | 3 | % | ||||||||
Net revenue for the six months ended June 30, 2023 was $225.0 million, compared to $218.5 million for the six months ended June 30, 2022, an increase of $6.4 million, or 3%. The increase in net revenue was driven by an increase of $7.1 million, or 3% in net revenue for Advanced Wound Care products. This is partially offset by a decrease of $0.7 million, or 5% in net revenue for Surgical & Sports Medicine products.
Gross profit for the six months ended June 30, 2023 was $172.0 million, or 76% of net revenue, compared to $166.8 million, or 76% of net revenue, for the six months ended June 30, 2022, an increase of $5.2 million.
Operating expenses for the six months ended June 30, 2023 were $166.3 million, compared to $155.0 million for the six months June 30, 2022, an increase of $11.3 million. R&D expense was $22.1 million for the six months ended June 30, 2023, compared to $18.8 million in the six months ended June 30, 2022, an increase of $3.3 million. Selling, general and administrative expenses were $144.2 million for the six months ended June 30, 2023, compared to $136.2 million in the six months ended June 30, 2022, an increase of $8.0 million.
Operating income for the six months ended June 30, 2023 was $5.7 million, compared to operating income of $11.8 million for the six months ended June 30, 2022, a decrease of $6.1 million.
Total other expenses, net, for the six months ended June 30, 2023 were $1.2 million, compared to $1.5 million for the six months ended June 30, 2022, a decrease of $0.3 million.
Net income of $2.3 million for the six months ended June 30, 2023 or $0.02 per share, compared to net income of $7.8 million, or $0.06 per share for the six months ended June 30, 2022, a decrease of $5.5 million, or $0.04, per share.
Adjusted net income for the six months ended June 30, 2023 was $5.4 million compared to $12.2 million, for the six months ended June 30, 2022, a decrease of $6.7 million.
Adjusted EBITDA of $19.2 million for the six months ended June 30, 2023, compared to an Adjusted EBITDA of $23.6 million, for the six months ended June 30, 2022, a decrease of $4.4 million.
Fiscal Year 2023 Guidance
The Company is withdrawing its previously announced fiscal year 2023 guidance, originally issued on May 10, 2023, due to the uncertainty resulting from the potential impact of the recently published local coverage determinations from Novitas, First Coast Services and CGS to limit coverage for treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to include only Apligraf and Dermagraft. The Company is currently unable to predict the impact that the recently published local coverage determinations will have on its financial position and operating results.
Second Quarter Earnings Conference Call
Financial results for the second fiscal quarter of 2023 will be reported after the market closes on August, 9th. Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for one year.
| ORGANOGENESIS HOLDINGS INC. | ||||||||
| UNAUDITED CONSOLIDATED BALANCE SHEETS | ||||||||
| (amounts in thousands, except share and per share data) | ||||||||
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 88,917 | $ | 102,478 | ||||
| Restricted cash | 591 | 812 | ||||||
| Accounts receivable, net | 93,615 | 89,450 | ||||||
| Inventory, net | 25,364 | 24,783 | ||||||
| Prepaid expenses and other current assets | 7,948 | 5,086 | ||||||
| Total current assets | 216,435 | 222,609 | ||||||
| Property and equipment, net | 111,825 | 102,463 | ||||||
| Intangible assets, net | 18,330 | 20,789 | ||||||
| Goodwill | 28,772 | 28,772 | ||||||
| Operating lease right-of-use assets, net | 43,544 | 43,192 | ||||||
| Deferred tax asset, net | 30,014 | 30,014 | ||||||
| Other assets | 1,393 | 1,520 | ||||||
| Total assets | $ | 450,313 | $ | 449,359 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of term loan, net of debt issuance costs | $ | 5,480 | $ | 4,538 | ||||
| Current portion of finance lease obligations | 209 | - | ||||||
| Current portion of operating lease obligations | 12,592 | 11,708 | ||||||
| Accounts payable | 27,390 | 32,330 | ||||||
| Accrued expenses and other current liabilities | 27,784 | 26,447 | ||||||
| Total current liabilities | 73,455 | 75,023 | ||||||
| Term loan, net of current portion and debt issuance costs | 63,489 | 66,231 | ||||||
| Finance lease obligations, net of current portion | 402 | - | ||||||
| Operating lease obligations, net of current portion | 40,495 | 41,314 | ||||||
| Other liabilities | 1,190 | 1,122 | ||||||
| Total liabilities | 179,031 | 183,690 | ||||||
| Commitments and contingencies (Note 18) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued | - | - | ||||||
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 132,040,400 and 131,647,677 shares issued; 131,311,852 and 130,919,129 shares outstanding at June 30, 2023 and December 31, 2022, respectively. | 13 | 13 | ||||||
| Additional paid-in capital | 314,838 | 310,957 | ||||||
| Accumulated deficit | (43,569 | ) | (45,301 | ) | ||||
| Total stockholders’ equity | 271,282 | 265,669 | ||||||
| Total liabilities and stockholders’ equity | $ | 450,313 | $ | 449,359 | ||||
| ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (amounts in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net revenue | $ | 117,316 | $ | 121,401 | $ | 224,958 | $ | 218,518 | ||||||||
| Cost of goods sold | 26,316 | 26,652 | 52,923 | 51,732 | ||||||||||||
| Gross profit | 91,000 | 94,749 | 172,035 | 166,786 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 70,317 | 72,609 | 144,151 | 136,187 | ||||||||||||
| Research and development | 10,938 | 10,205 | 22,140 | 18,792 | ||||||||||||
| Total operating expenses | 81,255 | 82,814 | 166,291 | 154,979 | ||||||||||||
| Income from operations | 9,745 | 11,935 | 5,744 | 11,807 | ||||||||||||
| Other expense, net: | ||||||||||||||||
| Interest expense | (594 | ) | (730 | ) | (1,243 | ) | (1,467 | ) | ||||||||
| Other income (expense), net | 28 | (21 | ) | 51 | (24 | ) | ||||||||||
| Total other expense, net | (566 | ) | (751 | ) | (1,192 | ) | (1,491 | ) | ||||||||
| Net income before income taxes | 9,179 | 11,184 | 4,552 | 10,316 | ||||||||||||
| Income tax expense | (3,863 | ) | (2,440 | ) | (2,205 | ) | (2,485 | ) | ||||||||
| Net income | $ | 5,316 | $ | 8,744 | $ | 2,347 | $ | 7,831 | ||||||||
| Net income, per share: | ||||||||||||||||
| Basic | $ | 0.04 | $ | 0.07 | $ | 0.02 | $ | 0.06 | ||||||||
| Diluted | $ | 0.04 | $ | 0.07 | $ | 0.02 | $ | 0.06 | ||||||||
| Weighted-average common shares outstanding | ||||||||||||||||
| Basic | 131,293,398 | 129,635,682 | 131,189,405 | 129,214,541 | ||||||||||||
| Diluted | 133,066,010 | 132,600,579 | 132,475,908 | 132,705,206 | ||||||||||||
| ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||
| (amounts in thousands, except share and per share data) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net Income | $ | 2,347 | $ | 7,831 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation | 4,922 | 2,875 | ||||||
| Amortization of intangible assets | 2,459 | 2,442 | ||||||
| Reduction in the carrying value of right-of-use assets | 3,893 | 3,649 | ||||||
| Non-cash interest expense | 215 | 217 | ||||||
| Deferred interest expense | 245 | 291 | ||||||
| Provision recorded for credit losses | 190 | 122 | ||||||
| Loss on disposal of property and equipment | 65 | 196 | ||||||
| Adjustment for excess and obsolete inventories | 3,464 | 5,228 | ||||||
| Stock-based compensation | 4,213 | 2,995 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (4,970 | ) | (6,485 | ) | ||||
| Inventory | (4,045 | ) | (3,441 | ) | ||||
| Prepaid expenses and other current assets | (2,874 | ) | (1,839 | ) | ||||
| Operating leases | (4,178 | ) | (3,472 | ) | ||||
| Accounts payable | (3,535 | ) | 2,671 | |||||
| Accrued expenses and other current liabilities | 1,091 | (1,697 | ) | |||||
| Other liabilities | 67 | 23 | ||||||
| Net cash provided by operating activities | 3,569 | 11,606 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (15,061 | ) | (12,840 | ) | ||||
| Net cash used in investing activities | (15,061 | ) | (12,840 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payments of term loan under the 2021 Credit Agreement | (1,875 | ) | (938 | ) | ||||
| Payments of withholding taxes in connection with RSUs vesting | (332 | ) | (646 | ) | ||||
| Proceeds from the exercise of stock options | - | 2,042 | ||||||
| Principal repayments of finance lease obligations | (83 | ) | (200 | ) | ||||
| Payment of deferred acquisition consideration | - | (608 | ) | |||||
| Net cash used in financing activities | (2,290 | ) | (350 | ) | ||||
| Change in cash, cash equivalents and restricted cash | (13,782 | ) | (1,584 | ) | ||||
| Cash, cash equivalents, and restricted cash, beginning of period | 103,290 | 114,528 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 89,508 | $ | 112,944 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | 2,608 | $ | 1,041 | ||||
| Cash paid for income taxes | $ | 3,022 | $ | 974 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Purchases of property and equipment included in accounts payable and accrued expenses | $ | 1,882 | $ | 6,546 | ||||
| Right-of-use assets obtained through lease obligations | $ | 4,253 | $ | 364 | ||||
| Shares issued for deferred acquisition consideration | $ | - | $ | 828 | ||||
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA and adjusted net income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA and adjusted net income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) (in thousands) | ||||||||||||||||
| Net Income | $ | 5,316 | $ | 8,744 | $ | 2,347 | $ | 7,831 | ||||||||
| Interest expense, net | 594 | 730 | 1,243 | 1,467 | ||||||||||||
| Income tax expense | 3,863 | 2,440 | 2,205 | 2,485 | ||||||||||||
| Depreciation | 2,228 | 1,528 | 4,922 | 2,875 | ||||||||||||
| Amortization | 1,229 | 1,221 | 2,459 | 2,442 | ||||||||||||
| EBITDA | 13,230 | 14,663 | 13,176 | 17,100 | ||||||||||||
| Stock-based compensation expense | 2,299 | 1,692 | 4,213 | 2,995 | ||||||||||||
| Restructuring charge (adjustment) (1) | (126 | ) | 643 | 1,782 | 907 | |||||||||||
| Settlement fee (2) | - | 1,600 | - | 2,600 | ||||||||||||
| Adjusted EBITDA | $ | 15,403 | $ | 18,598 | $ | 19,171 | $ | 23,602 | ||||||||
(1) Amounts reflect employee severance, retention and benefits as well as other exit costs associated with the Company’s restructuring activities.
(2) Amounts reflect the fee the Company paid to a GPO to settle previously disputed GPO fees.
The following table presents a reconciliation of GAAP net income to non-GAAP adjusted net income, for the periods presented:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (Unaudited) (in thousands) | (in thousands) | |||||||||||||||
| Net Income | $ | 5,316 | $ | 8,744 | $ | 2,347 | $ | 7,831 | ||||||||
| Amortization | 1,229 | 1,221 | 2,459 | 2,442 | ||||||||||||
| Restructuring charge (adjustment) (1) | (126 | ) | 643 | 1,782 | 907 | |||||||||||
| Settlement fee (2) | - | 1,600 | - | 2,600 | ||||||||||||
| Tax on above | (298 | ) | (935 | ) | (1,145 | ) | (1,606 | ) | ||||||||
| Adjusted net income | $ | 6,121 | $ | 11,273 | $ | 5,443 | $ | 12,174 | ||||||||
(1) Amounts reflect employee severance, retention and benefits as well as other exit costs associated with the Company’s restructuring activities.
(2) Amounts reflect the fee the Company paid to a GPO to settle previously disputed GPO fees.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2023 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products (including as a result of the recently published LCDs); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company may owe rebates to the federal government prospectively on certain of its products if more than a certain percentage of the product is not administered to a patient and is discarded (wasted) by providers; (6) the Company’s ability to raise funds to expand its business; (7) the Company has incurred losses in prior years and may incur losses in the future; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (10) the Company’s ability to maintain production of Affinity in sufficient quantities to meet demand; (11) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (12) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; and (13) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2022 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
| Last Trade: | US$4.05 |
| Daily Change: | 0.03 0.75 |
| Daily Volume: | 836,796 |
| Market Cap: | US$536.910M |
November 22, 2024 November 12, 2024 November 12, 2024 November 11, 2024 October 01, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
